stockrowBausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation (BLCO) Net income
Bausch + Lomb Corporation's net income for fiscal 2025 was −$352.0M, compared with −$305.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$103.0M. Over the past ten years it has ranged from −$352.0M (fiscal 2025) to $193.0M (fiscal 2021) — the current reading is the lowest in ten years. Net income has fallen for 4 consecutive fiscal years. Bausch + Lomb Corporation ranks 45th of 51 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$352.0M | — |
| FY2024 | −$305.0M | — |
| FY2023 | −$248.0M | — |
| FY2022 | $15.0M | (92.23%) |
| FY2021 | $193.0M | — |
| FY2020 | −$17.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $35.0M | — |
| Jun 2026 | −$10.0M | — |
| Mar 2026 | −$70.0M | — |
| Dec 2025 | −$58.0M | — |
| 20 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| COO The Cooper Companies, Inc. compare | $570.3M |
| ALGN Align Technology, Inc. compare | $413.6M |
| AVTR Avantor, Inc. compare | $337.2M |
| ATR AptarGroup, Inc. compare | $267.9M |
| MMSI Merit Medical Systems, Inc. compare | $160.1M |
| RGEN Repligen Corporation compare | −$11.8M |
| BLCO Bausch + Lomb Corporation | −$103.0M |
| MMED MiniMed Group, Inc. compare | −$320.0M |
| TFX Teleflex Incorporated compare | −$1.0B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BLCO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement